Member Info for chester18

Thank you esmerelda, I think that stops the speculation in its tracks.

Thanks Phil, That sorts that out. There must be some AIM related or Legal reason to do it as it may just be good compliance. I'd rather we got to the end of both current phase ll trials under our own steam, rather than be taken out on the cheap, so to speak. Let's just keep enjoying the journey...

Hi eggonaroll, I saw your comment on the recent RNS of the number of shares. It does seem odd that they would do that and in all the companies where I own shares I've never seen that before. Saying that I've never held shares where there has been a take over or buyout. My question is to anyone who may know, 'under what circumstances is it necessary to RNS the number of shares currently issued" Just very intrigued, and thanks egg for pointing it out... Chester

I have met a guy a couple of times who was on the board of five or six companies as non exec. He said the main reason was given the appointments was because of his track record and most importantly the trust he had built up with institutional contacts over twenty five years. His contacts trusted his judgement when it came doing deals. I'm sure cross pollination happens so done correctly appointing the correct non exec's is key to a companies future success. We should take from his new appointment that he is indeed the right man to be our chairman. After all he can't sit around waiting for the FDA to stop saying, "The computer says no"..... Chester

The 29.5p was just a booking error that got reported and then correct in minutes. It happens and by accident "of course"..... Also the market capitalisation is just the share price multiplied by the number of shares so current price £3.10/share = £98.310M Hope that answers the question.

Hi Popes I remember all the bounces from 2.5p to 3.4p and back again and again and again. At least we now know that as the price rises we should be on firmer ground. Also the next update has the potential of getting us back to the mythical £5 / £6 range. That should put a smile on most LTH's faces....

Wanderlust you are most welcome. It is to all our benefit that we share with each other what little knowledge we have. I have been trying to be a smart investor for 20 years and its a pleasure to be holding some Reneuron at this point in their evolution from research and development into Bio-pharma company. Hopefully with mulitple approved products. As has been said before, the share price will not go up in a nice straight line and the nearer to a fully approved drug we are the more large investors will want in. So your shares and mine will be wanted and the MM's will try all their best tricks to get them. It's going to be positive updates from Rene that will push the share to greater heights. Any negative news will cause a backward step. This is pioneering stuff and so far 12 years of difficult science has produced only positively amazing results. For the current patients sake and maybe one day our own sake let it be only positive news. Chester.

Cheers Manifesto I'm going have to toughen up and start bigging up Rene so I can claim ramping status, but on the other hand perhaps I shouldn't. Blown it again.... I'll never get on the list..

Didn't even get a mention and I try my best....

Hi Wanderlust I think quite a few will have bought in early enough to be holding decent profits. Only natural to worry that a paper profit is going to slip away. Plus the Market Makers are dammed good at their art.... I want to point out that the RP results are fantastic but we also have the Exsomes manufacturing agreement and 110 patients in the Piecese lll - Phase ll CTX trails for Stroke running in 40 sites in the USA right now. The first data from that study will be collected at 6 months from first injections (1st patient was 24th Jan 2019) and the full clinical read out and report to market early in 2020. My point is that anyone who fully understands just where RENE are at the moment would not sell at these prices. Though as I said the MM's are so good at what they do.

TYPO, So come on TRX should have said.... It's late and yes I'm also a holder of the other company. Saying that I hold a far greater number of shares and value in Tissue Regenix.

I'm presuming that we should see the final published accounts plus an update on how the business has been doing so far in 2019, any time soon. It was late April last year so expect it will be very similar this. How the first four months has progressed will be crucial to how 2019 full year results will turn out. So come on RENE give us something to shout about.

Still think this will be £3.80 / £4.00 by the end of the week. If someone is prepared to buy £600k worth in one trade you can be assured they think the true value right now is & £5 or £6. If the price falls some people will also see it as an opportunity. Remember saving a persons eyesight does not happen everyday, it is truly amazing and the smart money will end up owning these shares. This share is going to get traded but I'm not brave enough to sell and try to buy back, I know it's what some do but its not for me. Happy to Stick not Twist..... Chester

There are always retraces it's how the support is built at higher and higher prices. On the subject of Lazzarous obviously the reincarnation of Purpleackey the slayer of the truth. Best ignored as his posts they will be tailored to cause a response. Very cleverly done. Chester

Sorry guys our posts crossed...

The Directors (together with their families and their family trusts and pension scheme arrangements) in aggregate hold 418,575 ordinary shares in the Company, representing 1.32% of the Company’s current issued share capital.

36.63% of the issued share capital is not in public hands.

Hi Kingdom 101,

This is info from Reneurons own website.
I don't know if anyone else can elaborate a little more on who else may hold under 3%.

The Company is aware of the following significant (3% or greater)
shareholdings in the Company’s ordinary shares:

Woodford Investment 35.39%
Arthurian Life Sciences 9.48%

Chester

There's a very good chance that Fridays presentation will have filtered through the news channels over the weekend. I would expect some new money entering the share and if we're lucky this will now be on the radar of US investors. My guess would be that we see a rise to £3.80 or £4.00 by the end if the week. The next big vault forward will be on further positive data from Phase 2b or Chort 6. Or if Rene have another ace up their sleeve in the form of a deal (or two)... getting greedy.... The price is bound to flip about its going be traded the hell out of and we're on the AIM platform. The main thing is, more positive news from the company the better to keep the share price going forward. Chester

Hi grizzlyb, There is no disputing the facts. I think the confusion is between Phase 1, which we all know is the starting point, mainly to prove safety. And Cohorts 1 to 6... If the summary you posted had said Phase 1 toxicology testing of Cohorts 1,2, 3 & 4 it would have had less impact. Unless your in the science community your main sources of information is here on these types of discussion boards or the news. I for instance knew we had started the US trials but couldn't tell you exactly how Cohort's 1 - 4 had turned out, only Phase I had completed and we were approved to start Phase 2. So in summary, a storm in a tea cup, a misunderstanding of the intent so please let's go back to enjoying the fact that we're all in a share that's doing good. Chester

Hi grizzilyb Not a problem your right the facts are important. And the fact is what Reneuron has achieved, so far, is incredible and I hope that it is just the beginning of the story for everybody that can benifit from their hardwork and diligence. Chester

OK got it now, because you were talking Phase I (Toxicology) and my brain is now concentrating on the current remarkably stunning Phase ll progress / success. I think all the phase one stuff is irrelevant because it needs to be done but isn't the main aim of the trials. Success in current Phase llb trials will be the next big news in RP. We've also got the other trial in stroke patients and the possibility of other pharma deals being announced. There, that's much better than dragging up phase one irrelevance, don't you think..... Chester